Risk factors for hepatic veno-occlusive disease: A retrospective unicentric study in 116 children autografted after a high-dose BU-thiotepa regimen

A. Cacchione, A. LeMaitre, D. Valteau Couanet, E. Benhamou, L. Amoroso, N. Simonnard, O. Hartmann

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

At our Institute, during the last decade, the incidence of hepatic veno-occlusive disease (HVOD) appears to be on the increase among pediatric patients treated with BU-thiotepa (BU-TTP)-conditioning regimen. We thus performed a retrospective analysis to identify the risk factors for HVOD, which could explain such a change. In total, 116 patients treated at Institut Gustave Roussy, between May 1998 and December 2005 were eligible for this study having received BU-TTP as their first high-dose chemotherapy regimen, followed by autologous hematopoietic SCT (AHSCT). According to McDonald's clinical criteria, HVOD was diagnosed in 31% of these children. Demographic, clinical, biological and therapeutic parameters were evaluated in uni- and multivariate analyses that showed a significant correlation between previous carboplatin therapy and risk of developing post transplant HVOD (P=0.028). Comparable results were found for etoposide (P=0.048). In addition, a correlation between HVOD and risk of post transplant death was linked to its association with other types of organ failure (P=0.029). This study demonstrates that previous VPCARBO administration in conventional chemotherapy significantly increases the risk of HVOD among brain tumor patients later consolidated with BU-TTP followed by AHSCT.

Original languageEnglish
Pages (from-to)449-454
Number of pages6
JournalBone Marrow Transplantation
Volume42
Issue number7
DOIs
Publication statusPublished - 2008

Fingerprint

Hepatic Veno-Occlusive Disease
Thiotepa
Retrospective Studies
Transplants
Drug Therapy
Carboplatin
Etoposide
Brain Neoplasms
Multivariate Analysis
Demography
Pediatrics
Incidence
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Risk factors for hepatic veno-occlusive disease : A retrospective unicentric study in 116 children autografted after a high-dose BU-thiotepa regimen. / Cacchione, A.; LeMaitre, A.; Couanet, D. Valteau; Benhamou, E.; Amoroso, L.; Simonnard, N.; Hartmann, O.

In: Bone Marrow Transplantation, Vol. 42, No. 7, 2008, p. 449-454.

Research output: Contribution to journalArticle

Cacchione, A. ; LeMaitre, A. ; Couanet, D. Valteau ; Benhamou, E. ; Amoroso, L. ; Simonnard, N. ; Hartmann, O. / Risk factors for hepatic veno-occlusive disease : A retrospective unicentric study in 116 children autografted after a high-dose BU-thiotepa regimen. In: Bone Marrow Transplantation. 2008 ; Vol. 42, No. 7. pp. 449-454.
@article{097f2af255ad407189751f3c0a1ddc28,
title = "Risk factors for hepatic veno-occlusive disease: A retrospective unicentric study in 116 children autografted after a high-dose BU-thiotepa regimen",
abstract = "At our Institute, during the last decade, the incidence of hepatic veno-occlusive disease (HVOD) appears to be on the increase among pediatric patients treated with BU-thiotepa (BU-TTP)-conditioning regimen. We thus performed a retrospective analysis to identify the risk factors for HVOD, which could explain such a change. In total, 116 patients treated at Institut Gustave Roussy, between May 1998 and December 2005 were eligible for this study having received BU-TTP as their first high-dose chemotherapy regimen, followed by autologous hematopoietic SCT (AHSCT). According to McDonald's clinical criteria, HVOD was diagnosed in 31{\%} of these children. Demographic, clinical, biological and therapeutic parameters were evaluated in uni- and multivariate analyses that showed a significant correlation between previous carboplatin therapy and risk of developing post transplant HVOD (P=0.028). Comparable results were found for etoposide (P=0.048). In addition, a correlation between HVOD and risk of post transplant death was linked to its association with other types of organ failure (P=0.029). This study demonstrates that previous VPCARBO administration in conventional chemotherapy significantly increases the risk of HVOD among brain tumor patients later consolidated with BU-TTP followed by AHSCT.",
author = "A. Cacchione and A. LeMaitre and Couanet, {D. Valteau} and E. Benhamou and L. Amoroso and N. Simonnard and O. Hartmann",
year = "2008",
doi = "10.1038/bmt.2008.186",
language = "English",
volume = "42",
pages = "449--454",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Risk factors for hepatic veno-occlusive disease

T2 - A retrospective unicentric study in 116 children autografted after a high-dose BU-thiotepa regimen

AU - Cacchione, A.

AU - LeMaitre, A.

AU - Couanet, D. Valteau

AU - Benhamou, E.

AU - Amoroso, L.

AU - Simonnard, N.

AU - Hartmann, O.

PY - 2008

Y1 - 2008

N2 - At our Institute, during the last decade, the incidence of hepatic veno-occlusive disease (HVOD) appears to be on the increase among pediatric patients treated with BU-thiotepa (BU-TTP)-conditioning regimen. We thus performed a retrospective analysis to identify the risk factors for HVOD, which could explain such a change. In total, 116 patients treated at Institut Gustave Roussy, between May 1998 and December 2005 were eligible for this study having received BU-TTP as their first high-dose chemotherapy regimen, followed by autologous hematopoietic SCT (AHSCT). According to McDonald's clinical criteria, HVOD was diagnosed in 31% of these children. Demographic, clinical, biological and therapeutic parameters were evaluated in uni- and multivariate analyses that showed a significant correlation between previous carboplatin therapy and risk of developing post transplant HVOD (P=0.028). Comparable results were found for etoposide (P=0.048). In addition, a correlation between HVOD and risk of post transplant death was linked to its association with other types of organ failure (P=0.029). This study demonstrates that previous VPCARBO administration in conventional chemotherapy significantly increases the risk of HVOD among brain tumor patients later consolidated with BU-TTP followed by AHSCT.

AB - At our Institute, during the last decade, the incidence of hepatic veno-occlusive disease (HVOD) appears to be on the increase among pediatric patients treated with BU-thiotepa (BU-TTP)-conditioning regimen. We thus performed a retrospective analysis to identify the risk factors for HVOD, which could explain such a change. In total, 116 patients treated at Institut Gustave Roussy, between May 1998 and December 2005 were eligible for this study having received BU-TTP as their first high-dose chemotherapy regimen, followed by autologous hematopoietic SCT (AHSCT). According to McDonald's clinical criteria, HVOD was diagnosed in 31% of these children. Demographic, clinical, biological and therapeutic parameters were evaluated in uni- and multivariate analyses that showed a significant correlation between previous carboplatin therapy and risk of developing post transplant HVOD (P=0.028). Comparable results were found for etoposide (P=0.048). In addition, a correlation between HVOD and risk of post transplant death was linked to its association with other types of organ failure (P=0.029). This study demonstrates that previous VPCARBO administration in conventional chemotherapy significantly increases the risk of HVOD among brain tumor patients later consolidated with BU-TTP followed by AHSCT.

UR - http://www.scopus.com/inward/record.url?scp=54349112609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54349112609&partnerID=8YFLogxK

U2 - 10.1038/bmt.2008.186

DO - 10.1038/bmt.2008.186

M3 - Article

C2 - 18587430

AN - SCOPUS:54349112609

VL - 42

SP - 449

EP - 454

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 7

ER -